Beyond Air（XAIR）株式概要Beyond Air, Inc.は、商用化段階にある医療機器およびバイオ医薬品企業として事業を展開しています。 詳細XAIR ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長2/6過去の実績0/6財務の健全性2/6配当金0/6報酬収益は年間57.8%増加すると予測されています 同業他社や業界と比較して、良好な取引価格 リスク分析キャッシュランウェイが1年未満である 過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( $7M )US市場と比較した過去 3 か月間の株価の変動+1 さらなるリスクすべてのリスクチェックを見るXAIR Community Fair Values Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN94.2% undervaluedAnalystConsensusTarget•18d agoXAIR: Global Network Expansion Will Drive Long-Term Market Presence123016AN76.6% undervaluedAnalystLowTarget•2mo agoSlow Hospital Onboarding Will Constrain Revenue With Eventual Recovery6210AN96.7% undervaluedAnalystHighTarget•10mo agoAging Populations And Precision Medicine Will Reshape Respiratory Care1602Top Analyst NarrativesAN94.2% undervaluedAnalystConsensusTarget•18d agoXAIR: Global Network Expansion Will Drive Long-Term Market Presence123016AN76.6% undervaluedAnalystLowTarget•2mo agoSlow Hospital Onboarding Will Constrain Revenue With Eventual Recovery6210AN96.7% undervaluedAnalystHighTarget•10mo agoAging Populations And Precision Medicine Will Reshape Respiratory Care1602View all narrativesBeyond Air, Inc. 競合他社Intelligent Bio SolutionsSymbol: NasdaqCM:INBSMarket cap: US$5.4mGuided TherapeuticsSymbol: OTCPK:GTHPMarket cap: US$27.0mTenon MedicalSymbol: NasdaqCM:TNONMarket cap: US$5.1mSeaStar Medical HoldingSymbol: NasdaqCM:ICUMarket cap: US$19.8m価格と性能株価の高値、安値、推移の概要Beyond Air過去の株価現在の株価US$0.4752週高値US$4.7852週安値US$0.33ベータ0.221ヶ月の変化13.37%3ヶ月変化-34.08%1年変化-87.67%3年間の変化-99.43%5年間の変化-99.65%IPOからの変化-99.63%最新ニュースReported Earnings • Jun 28Full year 2026 earnings: EPS and revenues miss analyst expectationsFull year 2026 results: US$4.01 loss per share (improved from US$13.77 loss in FY 2025). Revenue: US$7.68m (up 107% from FY 2025). Net loss: US$33.2m (loss narrowed 29% from FY 2025). Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) also missed analyst estimates by 6.3%. Revenue is forecast to grow 50% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.お知らせ • Jun 27Beyond Air, Inc. Provides Revenue Guidance for the Year Ending December 31, 2026 and Year Ending December 31, 2027Beyond Air, Inc. provided revenue guidance for the year ending December 31, 2026 and year ending December 31, 2027. For the year 2026, the Company announced revenue guidance of $8 million for calendar year 2026, representing 15% growth compared with calendar year 2025. For calendar year 2027, the Company announced revenue guidance of $16-$18 million, representing more than 110% year-over-year growth at the midpoint compared with 2026 guidance and including the commercial launch of the second-generation LungFit PH system.お知らせ • Jun 23Beyond Air, Inc. to Report Q4, 2026 Results on Jun 26, 2026Beyond Air, Inc. announced that they will report Q4, 2026 results Pre-Market on Jun 26, 2026ナラティブの更新 • Jun 17XAIR: Hospital Access Expansion And Reverse Split Plans Will Support Future UpsideAnalysts have kept their Beyond Air price target broadly stable, with only a minor adjustment that reflects small tweaks to projected profit margins and future P/E assumptions rather than a change in the core outlook. What’s in the News for Beyond Air Beyond Air scheduled a Special Shareholders Meeting for June 18, 2026, to vote on a proposal that would allow the Board to carry out a reverse stock split of the company’s common stock at a ratio between 1-for-2 and 1-for-20, at any time up to one year after the meeting, subject to shareholder approval.ナラティブの更新 • Jun 03XAIR: Future Hospital Access Agreement Will Support Long Term Upside PotentialAnalysts now see fair value for Beyond Air at $8.00, down from $8.67, reflecting a slightly higher discount rate and marginally softer assumptions for revenue growth, profit margin, and future P/E multiples. What's in the News Beyond Air scheduled a special shareholder meeting for June 18, 2026 at 900 Stewart Avenue, Suite 301, Garden City, New York, to vote on key corporate matters.ナラティブの更新 • May 06XAIR: Later FDA Decision Will Still Drive Key Future InflectionNarrative Update Analysts have cut their price target on Beyond Air from $6 to $2, citing lower sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system, which they still view as central to its future revenue and profitability potential. Analyst Commentary Bearish analysts have reacted to the fiscal Q3 update by cutting their price target on Beyond Air to $2 from $6, highlighting what they see as a tougher setup for both growth and valuation in the near term.最新情報をもっと見るRecent updatesReported Earnings • Jun 28Full year 2026 earnings: EPS and revenues miss analyst expectationsFull year 2026 results: US$4.01 loss per share (improved from US$13.77 loss in FY 2025). Revenue: US$7.68m (up 107% from FY 2025). Net loss: US$33.2m (loss narrowed 29% from FY 2025). Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) also missed analyst estimates by 6.3%. Revenue is forecast to grow 50% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.お知らせ • Jun 27Beyond Air, Inc. Provides Revenue Guidance for the Year Ending December 31, 2026 and Year Ending December 31, 2027Beyond Air, Inc. provided revenue guidance for the year ending December 31, 2026 and year ending December 31, 2027. For the year 2026, the Company announced revenue guidance of $8 million for calendar year 2026, representing 15% growth compared with calendar year 2025. For calendar year 2027, the Company announced revenue guidance of $16-$18 million, representing more than 110% year-over-year growth at the midpoint compared with 2026 guidance and including the commercial launch of the second-generation LungFit PH system.お知らせ • Jun 23Beyond Air, Inc. to Report Q4, 2026 Results on Jun 26, 2026Beyond Air, Inc. announced that they will report Q4, 2026 results Pre-Market on Jun 26, 2026ナラティブの更新 • Jun 17XAIR: Hospital Access Expansion And Reverse Split Plans Will Support Future UpsideAnalysts have kept their Beyond Air price target broadly stable, with only a minor adjustment that reflects small tweaks to projected profit margins and future P/E assumptions rather than a change in the core outlook. What’s in the News for Beyond Air Beyond Air scheduled a Special Shareholders Meeting for June 18, 2026, to vote on a proposal that would allow the Board to carry out a reverse stock split of the company’s common stock at a ratio between 1-for-2 and 1-for-20, at any time up to one year after the meeting, subject to shareholder approval.ナラティブの更新 • Jun 03XAIR: Future Hospital Access Agreement Will Support Long Term Upside PotentialAnalysts now see fair value for Beyond Air at $8.00, down from $8.67, reflecting a slightly higher discount rate and marginally softer assumptions for revenue growth, profit margin, and future P/E multiples. What's in the News Beyond Air scheduled a special shareholder meeting for June 18, 2026 at 900 Stewart Avenue, Suite 301, Garden City, New York, to vote on key corporate matters.ナラティブの更新 • May 06XAIR: Later FDA Decision Will Still Drive Key Future InflectionNarrative Update Analysts have cut their price target on Beyond Air from $6 to $2, citing lower sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system, which they still view as central to its future revenue and profitability potential. Analyst Commentary Bearish analysts have reacted to the fiscal Q3 update by cutting their price target on Beyond Air to $2 from $6, highlighting what they see as a tougher setup for both growth and valuation in the near term.ナラティブの更新 • Apr 21XAIR: Later Regulatory Decision Will Still Support Long Term Upside PotentialAnalysts have cut their price target on Beyond Air to $2 from $6, citing reduced sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system as key reasons for the reset. Analyst Commentary Bullish Takeaways Bullish analysts still point to the second generation LungFit PH system as the main potential driver for higher long term revenue and margin expansion, which they see as central to justifying a higher valuation over time.お知らせ • Apr 11Beyond Air, Inc. Receives Notice of Non-Compliance with Nasdaq Listing RuleOn April 7, 2026, Beyond Air, Inc. (the Company) received a written notification (the Notice) from the staff of the Listing Qualifications Department (the Staff) of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it no longer satisfies the $1.00 bid price requirement set in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the continued listing minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business days (collectively, the Bid Price Rule). Based on the closing bid price of the Company's common stock, par value $0.0001 per share (the Common Stock), for the thirty (30) consecutive business days from February 23, 2026 to April 6, 2026, the Company no longer satisfies the Bid Price Rule. While companies are typically afforded a 180-calendar day compliance period to comply with the Bid Price Rule, the Notice stated that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company was not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that the Company effected a reverse stock split over the prior one-year period. The Company effected a 1-for-20 reverse stock split on July 14, 2025. The Notice stated that the Company's securities will be subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the Panel) by April 14, 2026. Accordingly, the Company intends to timely request a hearing before the Panel, and at which point, such timely request will automatically stay any further suspension or delisting action by Nasdaq pending the Panel's decision. During the appeal process with the Panel, the Common Stock will continue to be listed and trade on Nasdaq. However, there can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to regain compliance and thereafter maintain its listing on Nasdaq. The Company intends to actively monitor the bid price of its Common Stock and is considering available options to regain compliance with the Nasdaq listing requirements, including such actions as effecting a reverse stock split to maintain its Nasdaq listing.ナラティブの更新 • Apr 07XAIR: Later FDA Decision Will Still Unlock Key Future InflectionNarrative Update The analyst consensus price target for Beyond Air has shifted to $2, down from $6, as analysts point to reduced near term sales assumptions and a later FDA decision timeline for the second generation LungFit PH system, while still highlighting its potential importance for future revenue growth and profitability. Analyst Commentary Recent Street research reflects a more cautious stance on Beyond Air, with bearish analysts recalibrating expectations around both timing and scale of potential revenue from the second generation LungFit PH system.お知らせ • Mar 28+ 1 more updateSteve Lisi Steps Down from the Board of Directors of Beyond Air, Inc, Effective March 27, 2026Beyond Air, Inc. announced that Steve Lisi has stepped down from the Board of Directors, effective March 27, 2026 to pursue other opportunities. For the past nine years, Mr. Lisi has led Beyond Air, guiding the development and launch of the Company’s LungFit PH. Under his leadership, the Company successfully brought this revolutionary technology to market and established a strong foundation for the LungFit franchise to accelerate Beyond Air’s growth.ナラティブの更新 • Mar 24XAIR: Extended FDA Timeline Will Still Set Up Key Future InflectionAnalysts have cut their price target for Beyond Air to $2 from $6, citing revised sales timelines, with FDA approval for the second generation LungFit PH system now expected at the end of 2026, while still viewing that potential commercialization as central to future revenue growth and profitability. Analyst Commentary Recent price target revisions highlight a clear divide between long term optimism around LungFit PH and shorter term caution around execution and timing.ナラティブの更新 • Mar 10XAIR: Future Regulatory Milestone And Capital Raise Will Underpin Potential UpsideAnalysts have cut their price target on Beyond Air to $2 from $6, citing updated sales estimates and a later expected FDA decision for the second generation LungFit PH system as key drivers of their revised outlook. Analyst Commentary Bearish analysts are signaling a more cautious stance on Beyond Air, with the latest research move cutting the price target to $2 from $6 and explicitly tying that change to revised expectations around the LungFit PH opportunity and timing.New Risk • Feb 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.76m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings are forecast to decline by an average of 0.7% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (139% increase in shares outstanding). Market cap is less than US$10m (US$9.76m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$33m net loss in 2 years).ナラティブの更新 • Feb 23XAIR: Later FDA Decision Will Still Support Long Term Upside PotentialAnalysts have cut their average price target for Beyond Air from about $12.33 to $8.67, reflecting updated expectations for slower revenue growth, a higher discount rate, and a higher future P/E multiple as they factor in revised sales estimates tied to the later FDA decision timing for the second generation LungFit PH system. Analyst Commentary Bullish Takeaways Bullish analysts still frame the second generation LungFit PH system as a central driver for Beyond Air's long term revenue profile, pointing to commercialization of this product as a potential turning point for the business once regulatory milestones are met.Price Target Changed • Feb 20Price target increased by 16% to US$12.00Up from US$10.33, the current price target is an average from 2 analysts. New target price is 1,088% above last closing price of US$1.01. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$3.88 next year compared to a net loss per share of US$13.77 last year.New Risk • Feb 20New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings are forecast to decline by an average of 0.7% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (139% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$33m net loss in 2 years). Market cap is less than US$100m (US$11.4m market cap).Reported Earnings • Feb 16Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2026 results: US$0.85 loss per share (improved from US$2.96 loss in 3Q 2025). Revenue: US$2.19m (up 105% from 3Q 2025). Net loss: US$7.34m (loss narrowed 44% from 3Q 2025). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) missed analyst estimates by 4.0%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US.New Risk • Feb 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$37m Forecast net loss in 2 years: US$26m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Shareholders have been substantially diluted in the past year (139% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$26m net loss in 2 years). Market cap is less than US$100m (US$10.7m market cap).お知らせ • Feb 13+ 1 more updateBeyond Air, Inc. Maintains Earnings Guidance for the Fiscal Year Ending March 31, 2026Beyond Air, Inc. maintained earnings guidance for the fiscal year ending March 31, 2026. For the year, the company maintained its revenue guidance of $8 million to $10 million.ナラティブの更新 • Feb 09XAIR: Bullish Coverage And New Capital Raise Will Support Future UpsideAnalysts now see Beyond Air's fair value holding at $6.00 per share, with a slightly higher discount rate and modestly adjusted revenue growth, profit margin, and future P/E assumptions following fresh bullish coverage that supports a constructive long term thesis on the stock. Analyst Commentary Recent coverage frames Beyond Air as a higher risk, higher reward idea, with the current fair value estimate of US$6.00 per share sitting against a backdrop of both optimism and clear caution.お知らせ • Jan 27Beyond Air, Inc. to Report Q3, 2026 Results on Feb 13, 2026Beyond Air, Inc. announced that they will report Q3, 2026 results Pre-Market on Feb 13, 2026ナラティブの更新 • Jan 25XAIR: Expanded Distribution And Fresh Capital Will Support Future UpsideAnalysts have kept their fair value target for Beyond Air steady at US$6.00, while adjusting their models to reflect updated assumptions on discount rate, revenue growth, profit margin and future P/E following recent bullish Street research coverage. Analyst Commentary While the latest Street coverage has been supportive, some bearish analysts continue to flag risks that they believe are not fully captured in the current US$6.00 fair value estimate.お知らせ • Jan 14+ 1 more updateXTL Biopharmaceuticals Ltd. (TASE:XTLB) signed a letter of intent to acquire 85% stake in NeuroNos Limited from Beyond Air, Inc. (NasdaqCM:XAIR).XTL Biopharmaceuticals Ltd. (TASE:XTLB) signed a letter of intent to acquire 85% stake in NeuroNos Limited from Beyond Air, Inc. (NasdaqCM:XAIR) on January 13, 2026. A cash consideration of $1 million will be paid by XTL Biopharmaceuticals Ltd. The consideration consists of American Depositary Shares of XTL Biopharmaceuticals Ltd. to be issued as shall be required for Beyond Air, Inc. to beneficially own, as of the closing date of the Transaction, 19.99% of the issued and outstanding share capital of XTL Biopharmaceuticals Ltd. and three-year warrants of XTL Biopharmaceuticals Ltd. to be issued in such amount as necessary to ensure that Beyond Air, Inc. shall continue to maintain the Beneficial Ownership in relation to the exercise of certain existing XTL Biopharmaceuticals Ltd. warrants and any other issuances to employees and officers of NeuroNOS. Cash milestone payments in an aggregate amount of up to US$5,500,000, subject to the achievement of certain specified clinical and regulatory milestones, with an option for XTL Biopharmaceuticals Ltd., under certain circumstances, to discharge all such milestone payment obligations by making a single lump sum cash payment of US$4,000,000. Additionally, the LOI includes the payment of commercial milestone amounts by XTL Biopharmaceuticals Ltd. to Beyond Air, Inc based on cumulative net sales of the first NeuroNOS product, ranging from US$2,000,000 to US$12,500,000, upon attainment of specified net sales thresholds. Hence, XTL Biopharmaceuticals Ltd. will pay an earnout/contingent payment of $18 million cash. As part of consideration, $19 million is paid towards common equity of NeuroNos Limited. The transaction will be financed through equity investment of $2 million. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, consummation of due diligence investigation, definitive agreement and third party approval needed. The LOI contemplates that XTL intends to extend to the other shareholders of NeuroNOS, who collectively hold approximately 15% of the issued and outstanding share capital of NeuroNOS not owned by XAIR, the opportunity, exercisable within a specified period following the consummation of the Transaction, to exchange their Remaining Shares for ordinary shares of XTL, on terms and conditions to be set forth in the definitive agreements.New Risk • Jan 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 45% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (45% average weekly change). Shareholders have been substantially diluted in the past year (122% increase in shares outstanding). Market cap is less than US$10m (US$7.02m market cap).ナラティブの更新 • Jan 11XAIR: Expanded Global Distribution And Recent Financing Will Support Future UpsideAnalysts have revised their price target for Beyond Air to US$6.00, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E multiples, which leaves the fair value estimate unchanged at US$6.00. What's in the News Beyond Air updated its earnings guidance for the fiscal year ending March 31, 2026, with revenue now guided to a range of US$8 million to US$10 million (Corporate guidance).お知らせ • Jan 01+ 1 more updateBeyond Air, Inc. Announces Executive Changes, Effective as of January 5, 2026Beyond Air, Inc. announced on December 24, 2025, the Board of Directors of the company approved the appointment of Daniel Moorhead as the Company’s principal financial officer and principal accounting officer, effective as of January 5, 2026 (the “Effective Date”). Mr. Moorhead will replace Denton “Duke” Dewrell as the Company’s principal financial officer and principal accounting officer as of the Effective Date. Mr. Dewrell had temporarily assumed the role and responsibility of the principal financial officer and principal accounting officer of the Company, and will remain employed by the Company as its controller. Mr. Moorhead, age 53, most recently served as the Chief Financial Officer of Zynex, Inc. from June 2017 to August 2025. Prior to his role with Zynex, Mr. Moorhead previously served as Chief Financial Officer of Evolving Systems, Inc. from January 2016 until May 2017, after having served as Vice President of Finance & Administration from December 2011 through December 2015 and in other financial management roles from 2002-2005 and 2008-2011. Mr. Moorhead is a CPA and holds a B.B.A. in Accounting from the University of Northern Colorado.ナラティブの更新 • Dec 26XAIR: Expanded Global Distribution And New Financing Will Support Upside PotentialAnalysts have modestly raised their price target on Beyond Air to reflect a slightly higher long term growth outlook and valuation multiple, while incorporating a more conservative discount rate and largely unchanged profit margin assumptions. What's in the News Signed multiple new international distribution agreements for LungFit PH across Germany, Brazil, Austria, the Netherlands and Sri Lanka, bringing total coverage to 39 countries and over three billion people (Key Developments).お知らせ • Dec 22Beyond Air, Inc., Annual General Meeting, Jan 30, 2026Beyond Air, Inc., Annual General Meeting, Jan 30, 2026. Location: 900 stewart avenue, suite 301, garden city, new york 11530, new york United Statesナラティブの更新 • Dec 12XAIR: Stronger Revenue Outlook And Financing Will Support Future Upside PotentialAnalysts have raised their price target on Beyond Air to 6.00 dollars from 5.00 dollars, citing slightly stronger expected revenue growth, modestly improved profit margins, and a higher anticipated future price to earnings multiple despite a higher discount rate. What's in the News Chief Financial Officer Doug Larson has resigned to pursue another opportunity and will remain in his role until December 5, 2025.お知らせ • Nov 27Beyond Air, Inc. Announces CFO Changes, Effective December 5, 2025Beyond Air, Inc. announced that Doug Larson has resigned as Chief Financial Officer to pursue another opportunity. Mr. Larson will continue to serve as CFO through December 5, 2025, at which time the CFO responsibilities at the Company will be assumed on an interim basis by Duke Drewell, the Company’s Controller. Beyond Air has launched a search for a permanent successor. Mr. Larson will serve in an advisory role at the Company through calendar year end 2025 to support a smooth transition. Mr. Larson’s departure is not the result of any disagreements with the Company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices.New Risk • Nov 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.85m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (122% increase in shares outstanding). Market cap is less than US$10m (US$9.85m market cap).Major Estimate Revision • Nov 17Consensus revenue estimates fall by 36%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$13.4m to US$8.58m. Forecast losses increased from -US$3.47 to -US$3.74 per share. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target down from US$12.33 to US$10.33. Share price fell 21% to US$1.38 over the past week.Reported Earnings • Nov 12Second quarter 2026 earnings: EPS and revenues miss analyst expectationsSecond quarter 2026 results: US$1.25 loss per share (improved from US$5.67 loss in 2Q 2025). Revenue: US$1.82m (up 128% from 2Q 2025). Net loss: US$7.94m (loss narrowed 41% from 2Q 2025). Revenue missed analyst estimates by 28%. Earnings per share (EPS) also missed analyst estimates by 58%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US.お知らせ • Nov 11+ 1 more updateBeyond Air, Inc. Announces Executive ChangesBeyond Air, Inc. announced that Board member Bob Goodman as Interim Chief Commercial Officer to lead commercial strategy and team transitioning from David Webster. Bob brings decades of commercial leadership across medtech and pharma, including senior roles at BioTelemetry and Philips Healthcare, and will oversee U.S. and international commercial strategy, team expansion, and channel optimization. Appointed Robert (Bob) Goodman interim Chief Commercial Officer following the departure of David Webster. Robert, who joined the Board of Beyond Air in June 2025, has held key leadership roles at a range of high-performing organizations, including BioTelemetry, Philips Healthcare, Cardiocore, Thermo Fisher Scientific, and Pfizer. His career spans public companies, private equity–backed businesses, and early-stage ventures, where he has consistently driven innovation, operational scale, and commercial success.お知らせ • Nov 06Beyond Air, Inc. announced that it expects to receive $32.05 million in funding from Streeterville Capital, LLCBeyond Air, Inc. announced that it has entered into an equity purchase agreement to issue common shares for gross proceeds of $20,000,000 and also entered into a note purchase agreement to issue secured non-convertible promissory note in the principal amount of $12,050,000 for gross proceeds of $12,050,000 for aggregate proceeds of $32,050,000 on November 4, 2025. The transaction includes participation from new investor, Streeterville Capital, LLC. The note will accrue interest at the rate of 15% per annum, with no interest accruing for the first 12 months following issuance and will mature in 24 months following the date of issuance. The equity purchase agreement will terminate on the earlier of the date on which the investor shall have purchased put shares pursuant the agreement equal to the maximum commitment amount, within 24 months after the date of the agreement, written notice of termination by the company to the investor or the date that, pursuant to or within the meaning of any bankruptcy law, the company commences a voluntary case or any person commences a proceeding against the company, a custodian is appointed for the company or for all or substantially all of its property or the company makes general assignment for the benefit of its creditors. The company agreed to pay $50,000 to Streeterville to cover its transaction costs, resulting in the company receiving net proceeds of $32,000,000. On the same date the company issued secured promissory note in the principal amount of $12,050,000 for gross proceeds of $12,050,000 in its first tranche.ナラティブの更新 • Nov 01XAIR: Global Network Expansion Will Drive Long-Term Market PresenceAnalysts have modestly maintained their price target for Beyond Air at $12.33 per share. They cite steady expectations around revenue growth and profit margins, even though there have been minor adjustments to other financial assumptions.お知らせ • Oct 23Beyond Air, Inc. to Report Q2, 2026 Results on Nov 10, 2025Beyond Air, Inc. announced that they will report Q2, 2026 results on Nov 10, 2025ナラティブの更新 • Oct 18Global Expansion And Next-Generation Respiratory Care Will Transform MarketsAnalysts have raised their price target for Beyond Air from $11.20 to $12.33, reflecting improved revenue growth expectations and a notable increase in projected profit margins. What's in the News The global distribution network for LungFit PH has been expanded, with new agreements in Japan, South Korea, Costa Rica, Guatemala, and El Salvador.New Risk • Sep 23New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$42m Forecast net loss in 3 years: US$3.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$36m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (125% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$3.0m net loss in 3 years). Revenue is less than US$5m (US$4.8m revenue). Market cap is less than US$100m (US$12.3m market cap).ナラティブの更新 • Sep 04Global Expansion And Next-Generation Respiratory Care Will Transform MarketsWith minimal changes in both the discount rate and future P/E, Beyond Air’s consensus analyst price target remained effectively unchanged at $11.20. What's in the News Expanded global LungFit PH distribution network to 34 countries, including new agreements in Japan (with AMCO), South Korea, Costa Rica, Guatemala, and El Salvador.Major Estimate Revision • Aug 19Consensus revenue estimates decrease by 16%, EPS upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$16.0m to US$13.4m. EPS estimate increased from -US$4.08 to -US$4.03 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$19.40 to US$11.20. Share price fell 28% to US$2.29 over the past week.Reported Earnings • Aug 14First quarter 2026 earnings: EPS misses analyst expectationsFirst quarter 2026 results: US$1.53 loss per share (improved from US$5.32 loss in 1Q 2025). Revenue: US$1.76m (up 158% from 1Q 2025). Net loss: US$7.69m (loss narrowed 37% from 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 16%. Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.お知らせ • Aug 13Beyond Air, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending March 31, 2026Beyond Air, Inc. reaffirmed earnings guidance for the fiscal year ending March 31, 2026. For the period, the company, reaffirmed its revenue guidance of $12 million to $16 million.お知らせ • Jul 25Beyond Air, Inc. to Report Q1, 2026 Results on Aug 12, 2025Beyond Air, Inc. announced that they will report Q1, 2026 results on Aug 12, 2025Major Estimate Revision • Jul 23Consensus EPS estimates upgraded to US$4.31 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$5.00 to -US$4.31 per share. Revenue forecast unchanged from US$15.9m at last update. Medical Equipment industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$45.00 to US$36.60. Share price rose 3.7% to US$3.36 over the past week.お知らせ • Jun 19+ 1 more updateBeyond Air, Inc. Provides Earnings Guidance for the Quarter Ending June 30, 2025 and for the Year Ending March 31, 2025Beyond Air, Inc. provided earnings guidance for the quarter ending June 30, 2025 and for the year ending March 31, 2025. For the quarter, the company expects to report revenue of at least $1.7 million. For the year, the company is providing revenue guidance of $12 to $16 million.Reported Earnings • Jun 18Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: US$0.63 loss per share (improved from US$1.82 loss in FY 2024). Revenue: US$3.71m (up 220% from FY 2024). Net loss: US$46.6m (loss narrowed 23% from FY 2024). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) exceeded analyst estimates by 7.0%. Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.New Risk • Jun 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (88% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$9.8m net loss in 3 years). Revenue is less than US$5m (US$3.0m revenue). Market cap is less than US$100m (US$15.5m market cap).お知らせ • May 20Beyond Air, Inc. to Report Q4, 2025 Results on Jun 17, 2025Beyond Air, Inc. announced that they will report Q4, 2025 results on Jun 17, 2025新しいナラティブ • Apr 14The Next-Generation LungFit PH System Will Open New Markets International revenue could significantly impact growth due to CE Mark approval and distribution partnerships, especially in the EU.Recent Insider Transactions • Mar 18Independent Director recently bought US$250k worth of stockOn the 14th of March, Robert Carey bought around 1m shares on-market at roughly US$0.25 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$365k more in shares than they have sold in the last 12 months.Reported Earnings • Feb 11Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: US$0.15 loss per share (improved from US$0.50 loss in 3Q 2024). Revenue: US$1.07m (up 174% from 3Q 2024). Net loss: US$13.0m (loss narrowed 20% from 3Q 2024). Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 6.3%. Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.お知らせ • Feb 07Beyond Air Receives 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid RequirementBeyond Air, Inc. announced it received a notification from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has been granted an additional 180-day compliance period, or until August 4, 2025 to regain compliance with Nasdaq’s minimum bid price rule (Rule 5550(a)(2)). The notification has no immediate effect on the listing of the Company’s common stock, and the common stock will continue to trade on the Nasdaq Capital Market under the symbol "XAIR." Nasdaq’s determination is based on the Company meeting all other applicable requirements for listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period and, if necessary, by effecting a reverse share split. In a notification letter dated August 8, 2024, Nasdaq had first informed the Company that, based on the previous 30 consecutive business days, the Company’s common stock no longer met the minimum $1.00 bid price per share requirement and in accordance with Nasdaq’s Listing Rules, the Company was provided 180 calendar days, or until February 4, 2025, to regain compliance. The Company did not regain compliance with the minimum $1.00 bid price per share requirement during the first 180 calendar day compliance period and submitted a written request to Nasdaq’s staff to afford the Company an additional 180-day compliance period to cure the deficiency, which the Company was granted in a notification letter dated February 5, 2025. If at any time before August 4, 2025, the closing bid price of the Company’s security is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule and this matter will be closed. However, Nasdaq may, in its discretion, require the Company to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.お知らせ • Jan 28Beyond Air, Inc. to Report Q3, 2025 Results on Feb 10, 2025Beyond Air, Inc. announced that they will report Q3, 2025 results After-Market on Feb 10, 2025お知らせ • Jan 25Beyond Air®? Announces LungFit®? PH Receives Market Authorization in AustraliaBeyond Air, Inc. announced that the LungFit®? PH has received market authorization from the Australian Therapeutic Goods Administration (TGA) for sale as a Class IIb medical device to deliver nitric oxide, a vasodilator, generated by the device into the inspiratory limb of the patient breathing circuit of a ventilator in a way that provides a constant concentration of nitric oxide, as set by the user, to the patient throughout the inspired breath. LungFit PH, the first device in the LungFit therapeutic platform of nitric oxide generators, leverages the company's patented Ionizer®? technology and has already received FDA clearance in the United States and European CE Mark approval. LungFit PH uses Ionizer technology to generate unlimited on-demand NO from ambient air and deliver it to a ventilator circuit, regardless of dose or flow. The device uses a compressor to drive room air through a plasma chamber where pulses of electrical discharge are created between two electrodes. The LungFit PH system ionizes the nitrogen and oxygen molecules, forming NO with low levels of nitrogen dioxide (NO2) created as a byproduct. The gas is then passed through a Smart Filter, which removes toxic NO2 from the internal circuit. LungFit PH represents a significant step forward in sustainable healthcare solutions. Since the device generates NO conveniently and cleanly from ambient air, without the need for tanks or chemicals, it is highly energy-efficient, using only the power equivalent to a 60-watt light bulb. By eliminating the emissions associated with truck transport and cylinder refills, LungFit PH supports hospital sustainability initiatives, helping facilities reduce their carbon footprint while delivering critical care to patients. For the approved indications, the novel LungFit PH system is designed to deliver a dosage of NO to the lungs that is consistent with the current standard of care for delivery of 20 ppm NO, with a range of 0.5 ppm – 80 ppm (low concentration NO) for ventilated patients. Each Smart Filter will last 12 hours regardless of ventilator demands, and replacing a filter only takes seconds.お知らせ • Dec 04Beyond Air, Inc. Receives CE Mark in Europe for the LungFit PH SystemBeyond Air, Inc. announced European CE mark approval of the LungFit PH system. This CE mark approval allows Beyond Air to market LungFit PH in the European Union and all other countries that recognize this certification. LungFit PH, the first device in the LungFit therapeutic platform of nitric oxide generators, leverages the company's patented Ionizer technology and has already received FDA approval in the United States. Under the terms of Beyond Air’s existing commercialization agreement with Getz Healthcare for LungFit PH, Getz will make a $1 million milestone payment to Beyond Air upon CE mark certification. In addition, Beyond Air will receive ongoing royalty payments based on LungFit PH net sales. The partnership provides access to hospitals in Australia, New Zealand, Thailand, Philippines, Taiwan, Hong Kong, Malaysia, Pakistan, Singapore and Vietnam. The specific indications for LungFit PH under CE Mark certification include: 1) the treatment of infants > 34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation. 2) the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function. LungFit PH uses Ionizer technology to generate unlimited on-demand NO from ambient air and deliver it to a ventilator circuit, regardless of dose or flow. The device uses a compressor to drive room air through a plasma chamber where pulses of electrical discharge are created between two electrodes. The LungFit PH system ionizes the nitrogen and oxygen molecules, forming NO with low levels of nitrogen dioxide (NO2) created as a byproduct. The gas is then passed through a Smart Filter, which removes toxic NO2 from the internal circuit. LungFit PH represents a significant step forward in sustainable healthcare solutions. Since the device generates NO conveniently and cleanly from ambient air, without the need for tanks or chemicals, it is highly energy-efficient, using only the power equivalent to a 60-watt light bulb. By eliminating the emissions associated with truck transport and cylinder refills, LungFit PH supports hospital sustainability initiatives, helping facilities reduce their carbon footprint while delivering critical care to patients. For the approved indications, the novel LungFit PH system is designed to deliver a dosage of NO to the lungs that is consistent with the current standard of care for delivery of 20 ppm NO, with a range of 0.5 ppm – 80 ppm (low concentration NO) for ventilated patients. Each Smart Filter will last 12 hours regardless of ventilator demands, and replacing a filter only takes seconds. Potential customers can visit the LungFit PH website, www.lungfitph.com, for additional information, including the product label, and to sign up for updates.お知らせ • Nov 19Beyond Air, Inc. announced that it has received $3.35 million in funding from Avenue Capital Group, LLCOn November 18, 2024 Beyond Air, Inc. closed the transaction.Reported Earnings • Nov 14Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2025 results: US$0.28 loss per share (improved from US$0.51 loss in 2Q 2024). Net loss: US$13.4m (loss narrowed 18% from 2Q 2024). Revenue missed analyst estimates by 23%. Earnings per share (EPS) exceeded analyst estimates by 1.4%. Revenue is forecast to grow 92% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US.Major Estimate Revision • Nov 13Consensus revenue estimates decrease by 56%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$8.69m to US$3.79m. EPS estimate increased from -US$0.944 to -US$0.88 per share. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target down from US$3.75 to US$2.50. Share price was steady at US$0.48 over the past week.New Risk • Nov 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 128% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (128% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$4.5m net loss in 3 years). Revenue is less than US$5m (US$1.8m revenue). Market cap is less than US$100m (US$34.7m market cap).お知らせ • Oct 30Beyond Air, Inc. to Report Q2, 2025 Results on Nov 11, 2024Beyond Air, Inc. announced that they will report Q2, 2025 results After-Market on Nov 11, 2024お知らせ • Oct 10Beyond Air, Inc., Annual General Meeting, Dec 09, 2024Beyond Air, Inc., Annual General Meeting, Dec 09, 2024.お知らせ • Sep 27+ 1 more updateBeyond Air, Inc. Withdraws Its Previous Revenue Guidance for Fiscal Year 2025Beyond Air, Inc. is withdrawing its previous revenue guidance for fiscal year 2025.Recent Insider Transactions Derivative • Aug 25Chief Executive Officer of NeuroNOS notifies of intention to sell stockAmir Avniel intends to sell 180k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of August. If the sale is conducted around the recent share price of US$0.46, it would amount to US$83k. Since December 2023, Amir's direct individual holding has increased from 431.76k shares to 438.03k. Company insiders have collectively bought US$2.9m more than they sold, via options and on-market transactions, in the last 12 months.Major Estimate Revision • Aug 13Consensus EPS estimates upgraded to US$1.01 loss, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$9.67m to US$9.00m. 2025 losses expected to reduce from -US$1.16 to -US$1.01 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$5.17 to US$4.33. Share price fell 12% to US$0.43 over the past week.お知らせ • Aug 07Beyond Air, Inc. Provides Earnings Guidance for the Year 2025Beyond Air, Inc. provided earnings guidance for the year 2025, Revenue is expected to be greater than $10 million for Fiscal Year 2025.お知らせ • Jul 24Beyond Air, Inc. to Report Q1, 2025 Results on Aug 06, 2024Beyond Air, Inc. announced that they will report Q1, 2025 results After-Market on Aug 06, 2024お知らせ • Jul 09Beyond Air, Inc. announced that it has received $0.128 million in fundingOn July 9, 2024, Beyond Air, Inc. closed the transaction. The transaction included participation from two investors.お知らせ • Jul 03+ 3 more updatesBeyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell Small Cap Comp Value IndexBeyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell Small Cap Comp Value IndexMajor Estimate Revision • Jul 01Consensus revenue estimates decrease by 27%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$13.2m to US$9.67m. EPS estimate increased from -US$1.75 to -US$1.15 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$12.60 to US$5.88. Share price fell 60% to US$0.54 over the past week.Price Target Changed • Jun 25Price target decreased by 55% to US$5.88Down from US$13.00, the current price target is an average from 4 analysts. New target price is 805% above last closing price of US$0.65. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$1.15 next year compared to a net loss per share of US$1.82 last year.お知らせ • Jun 25Beyond Air, Inc. Updates Revenue Guidance for the Fiscal Year 2025Beyond Air, Inc. updated revenue guidance for the fiscal year 2025. For the year, the company updated revenue guidance to greater than $10 million, from the previous guidance of $12 million to $16 million.お知らせ • Jun 15Beyond Air Appoints David Webster as Chief Commercial Officer, Effective from July 8, 2024Beyond Air, Inc. announced the appointment of David Webster as Chief Commercial Officer of the Company, effective July 8, 2024. Mr. Webster has successfully developed and executed several commercial strategies for medical devices and therapeutics, primarily in the hospital space. Mr. Webster brings decades of experience in the life sciences industry, including leading several programs through clinical development, regulatory submissions, and global commercialization. Most recently, he served as Chief Executive Officer at Body Vision Medical, a medical device company dedicated to making artificial intelligence (AI)-driven real-time imaging navigation the standard of care for the diagnosis and treatment of endoluminal cancer. As CEO, he led the global commercialization of the Lung Vision system, expanding it into new medical applications. Prior to Body Vision, he spent nearly 18 years at NeuroLogica. During his tenure, he served as NeuroLogica’s Vice President of Global Sales and Marketing leading up to and after the company’s acquisition by Samsung Electronics Co. Ltd. in 2013. Following the acquisition, Mr. Webster served as Chief Marketing Officer and Chief Operating Officer for Samsung NeuroLogica. Mr. Webster holds a Master of Science degree in Business Administration and Management from Troy University and a Bachelor of Arts degree in Psychology from The Citadel.お知らせ • May 25Beyond Air, Inc. to Report Q4, 2024 Results on Jun 24, 2024Beyond Air, Inc. announced that they will report Q4, 2024 results on Jun 24, 2024お知らせ • Mar 23Beyond Air, Inc. has completed a Follow-on Equity Offering in the amount of $16.000003 million.Beyond Air, Inc. has completed a Follow-on Equity Offering in the amount of $16.000003 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 9,638,556 Price\Range: $1.66 Discount Per Security: $0.116 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 9,638,556 Transaction Features: Registered Direct OfferingNew Risk • Mar 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 6.2% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (US$689k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$78m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$74.8m market cap).お知らせ • Mar 22Beyond Air, Inc. has filed a Follow-on Equity Offering in the amount of $16.000003 million.Beyond Air, Inc. has filed a Follow-on Equity Offering in the amount of $16.000003 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 9,638,556 Price\Range: $1.66 Discount Per Security: $0.116 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 9,638,556 Transaction Features: Registered Direct OfferingMajor Estimate Revision • Feb 19Consensus revenue estimates decrease by 15%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$1.69m to US$1.43m. EPS estimate increased from -US$2.05 to -US$1.95 per share. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$13.00 unchanged from last update. Share price fell 9.8% to US$1.94 over the past week.お知らせ • Jan 27Beyond Air, Inc., Annual General Meeting, Mar 08, 2024Beyond Air, Inc., Annual General Meeting, Mar 08, 2024, at 16:30 US Eastern Standard Time. Location: Beyond Air, Inc., 900 Stewart Avenue, Suite 301 Garden City New York United States Agenda: To elect seven directors, each to hold office until the 2025 Annual Meeting of Stockholders and until his or her successor is elected and qualified; to ratify the appointment of Marcum LLP as independent registered public accounting firm for fiscal year ending March 31, 2024; to approve the Sixth Amended and Restated 2013 Equity Incentive Plan to increase the number of shares reserved for issuance by 3,000,000; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.お知らせ • Jan 19Beyond Air, Inc. to Report Q3, 2024 Results on Feb 12, 2024Beyond Air, Inc. announced that they will report Q3, 2024 results on Feb 12, 2024Recent Insider Transactions • Dec 22Independent Director recently bought US$2.0m worth of stockOn the 18th of December, Robert Carey bought around 1m shares on-market at roughly US$1.64 per share. This transaction increased Robert's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$3.6m more in shares than they have sold in the last 12 months.Major Estimate Revision • Nov 20Consensus revenue estimates fall by 40%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$2.86m to US$1.72m. Forecast losses increased from -US$1.90 to -US$2.02 per share. Medical Equipment industry in the US expected to see average net income growth of 22% next year. Consensus price target down from US$14.17 to US$12.50. Share price fell 26% to US$1.50 over the past week.New Risk • Nov 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$54m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Revenue is less than US$1m (US$298k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$43m net loss in 3 years). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Market cap is less than US$100m (US$44.8m market cap).Price Target Changed • Nov 15Price target decreased by 12% to US$13.00Down from US$14.83, the current price target is an average from 6 analysts. New target price is 829% above last closing price of US$1.40. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$1.89 next year compared to a net loss per share of US$1.86 last year.お知らせ • Oct 20Beyond Air, Inc. to Report Q2, 2024 Results on Nov 13, 2023Beyond Air, Inc. announced that they will report Q2, 2024 results on Nov 13, 2023株主還元XAIRUS Medical EquipmentUS 市場7D0.7%2.2%1.6%1Y-87.7%-19.0%18.6%株主還元を見る業界別リターン: XAIR過去 1 年間で-19 % の収益を上げたUS Medical Equipment業界を下回りました。リターン対市場: XAIRは、過去 1 年間で18.6 % のリターンを上げたUS市場を下回りました。価格変動Is XAIR's price volatile compared to industry and market?XAIR volatilityXAIR Average Weekly Movement16.0%Medical Equipment Industry Average Movement8.5%Market Average Movement7.3%10% most volatile stocks in US Market16.7%10% least volatile stocks in US Market3.2%安定した株価: XAIRの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: XAIRの 週次ボラティリティ は過去 1 年間で26%から16%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201154Bob Goodmanwww.beyondair.netBeyond Air, Inc.は、商用化段階にある医療機器およびバイオ医薬品企業として事業を展開しています。同社は、「Beyond Air」、「Beyond Cancer」、「NeuroNos」の各事業部門を通じて事業を行っています。同社は、新生児持続性肺高血圧症の治療薬として「Lungfit PH」を提供しています。 また、COVID-19や入院患者の細気管支炎を含む、ウイルス性市中肺炎などのウイルス性肺感染症の治療を目的とした「LungFit PRO」、および非結核性マイコバクテリア（NTM）の治療を目的とした「LungFit GO」の開発も進めています。 さらに、同社は固形がんの治療を目的とした第1相臨床試験段階にある超高濃度一酸化窒素（UNO）や、神経疾患の治療を目的とした選択的神経型一酸化窒素合成酵素（nNOS）阻害剤の開発も行っている。 また、自閉症スペクトラム障害やその他の神経疾患の治療を目的とした神経型一酸化窒素合成酵素阻害剤の商業化権を取得するため、エルサレム・ヘブライ大学のYissum Research Development Company, LTDと提携している。 同社は、以前はAIT Therapeutics, Inc.として知られていたが、2019年6月にBeyond Air, Inc.に社名を変更した。Beyond Air, Inc.は2011年に設立され、ニューヨーク州ガーデンシティに本社を置いている。もっと見るBeyond Air, Inc. 基礎のまとめBeyond Air の収益と売上を時価総額と比較するとどうか。XAIR 基礎統計学時価総額US$6.74m収益（TTM）-US$33.25m売上高(TTM)US$7.68m0.9xP/Sレシオ-0.2xPER（株価収益率XAIR は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計XAIR 損益計算書（TTM）収益US$7.68m売上原価US$7.43m売上総利益US$252.00kその他の費用US$33.50m収益-US$33.25m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-2.31グロス・マージン3.28%純利益率-432.99%有利子負債／自己資本比率354.9%XAIR の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/06 12:22終値2026/07/02 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Beyond Air, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Marie ThibaultBTIGMichael GormanBTIGJason KolbertD. Boral Capital LLC.4 その他のアナリストを表示
Reported Earnings • Jun 28Full year 2026 earnings: EPS and revenues miss analyst expectationsFull year 2026 results: US$4.01 loss per share (improved from US$13.77 loss in FY 2025). Revenue: US$7.68m (up 107% from FY 2025). Net loss: US$33.2m (loss narrowed 29% from FY 2025). Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) also missed analyst estimates by 6.3%. Revenue is forecast to grow 50% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.
お知らせ • Jun 27Beyond Air, Inc. Provides Revenue Guidance for the Year Ending December 31, 2026 and Year Ending December 31, 2027Beyond Air, Inc. provided revenue guidance for the year ending December 31, 2026 and year ending December 31, 2027. For the year 2026, the Company announced revenue guidance of $8 million for calendar year 2026, representing 15% growth compared with calendar year 2025. For calendar year 2027, the Company announced revenue guidance of $16-$18 million, representing more than 110% year-over-year growth at the midpoint compared with 2026 guidance and including the commercial launch of the second-generation LungFit PH system.
お知らせ • Jun 23Beyond Air, Inc. to Report Q4, 2026 Results on Jun 26, 2026Beyond Air, Inc. announced that they will report Q4, 2026 results Pre-Market on Jun 26, 2026
ナラティブの更新 • Jun 17XAIR: Hospital Access Expansion And Reverse Split Plans Will Support Future UpsideAnalysts have kept their Beyond Air price target broadly stable, with only a minor adjustment that reflects small tweaks to projected profit margins and future P/E assumptions rather than a change in the core outlook. What’s in the News for Beyond Air Beyond Air scheduled a Special Shareholders Meeting for June 18, 2026, to vote on a proposal that would allow the Board to carry out a reverse stock split of the company’s common stock at a ratio between 1-for-2 and 1-for-20, at any time up to one year after the meeting, subject to shareholder approval.
ナラティブの更新 • Jun 03XAIR: Future Hospital Access Agreement Will Support Long Term Upside PotentialAnalysts now see fair value for Beyond Air at $8.00, down from $8.67, reflecting a slightly higher discount rate and marginally softer assumptions for revenue growth, profit margin, and future P/E multiples. What's in the News Beyond Air scheduled a special shareholder meeting for June 18, 2026 at 900 Stewart Avenue, Suite 301, Garden City, New York, to vote on key corporate matters.
ナラティブの更新 • May 06XAIR: Later FDA Decision Will Still Drive Key Future InflectionNarrative Update Analysts have cut their price target on Beyond Air from $6 to $2, citing lower sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system, which they still view as central to its future revenue and profitability potential. Analyst Commentary Bearish analysts have reacted to the fiscal Q3 update by cutting their price target on Beyond Air to $2 from $6, highlighting what they see as a tougher setup for both growth and valuation in the near term.
Reported Earnings • Jun 28Full year 2026 earnings: EPS and revenues miss analyst expectationsFull year 2026 results: US$4.01 loss per share (improved from US$13.77 loss in FY 2025). Revenue: US$7.68m (up 107% from FY 2025). Net loss: US$33.2m (loss narrowed 29% from FY 2025). Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) also missed analyst estimates by 6.3%. Revenue is forecast to grow 50% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US.
お知らせ • Jun 27Beyond Air, Inc. Provides Revenue Guidance for the Year Ending December 31, 2026 and Year Ending December 31, 2027Beyond Air, Inc. provided revenue guidance for the year ending December 31, 2026 and year ending December 31, 2027. For the year 2026, the Company announced revenue guidance of $8 million for calendar year 2026, representing 15% growth compared with calendar year 2025. For calendar year 2027, the Company announced revenue guidance of $16-$18 million, representing more than 110% year-over-year growth at the midpoint compared with 2026 guidance and including the commercial launch of the second-generation LungFit PH system.
お知らせ • Jun 23Beyond Air, Inc. to Report Q4, 2026 Results on Jun 26, 2026Beyond Air, Inc. announced that they will report Q4, 2026 results Pre-Market on Jun 26, 2026
ナラティブの更新 • Jun 17XAIR: Hospital Access Expansion And Reverse Split Plans Will Support Future UpsideAnalysts have kept their Beyond Air price target broadly stable, with only a minor adjustment that reflects small tweaks to projected profit margins and future P/E assumptions rather than a change in the core outlook. What’s in the News for Beyond Air Beyond Air scheduled a Special Shareholders Meeting for June 18, 2026, to vote on a proposal that would allow the Board to carry out a reverse stock split of the company’s common stock at a ratio between 1-for-2 and 1-for-20, at any time up to one year after the meeting, subject to shareholder approval.
ナラティブの更新 • Jun 03XAIR: Future Hospital Access Agreement Will Support Long Term Upside PotentialAnalysts now see fair value for Beyond Air at $8.00, down from $8.67, reflecting a slightly higher discount rate and marginally softer assumptions for revenue growth, profit margin, and future P/E multiples. What's in the News Beyond Air scheduled a special shareholder meeting for June 18, 2026 at 900 Stewart Avenue, Suite 301, Garden City, New York, to vote on key corporate matters.
ナラティブの更新 • May 06XAIR: Later FDA Decision Will Still Drive Key Future InflectionNarrative Update Analysts have cut their price target on Beyond Air from $6 to $2, citing lower sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system, which they still view as central to its future revenue and profitability potential. Analyst Commentary Bearish analysts have reacted to the fiscal Q3 update by cutting their price target on Beyond Air to $2 from $6, highlighting what they see as a tougher setup for both growth and valuation in the near term.
ナラティブの更新 • Apr 21XAIR: Later Regulatory Decision Will Still Support Long Term Upside PotentialAnalysts have cut their price target on Beyond Air to $2 from $6, citing reduced sales estimates and a longer timeline for potential FDA approval of the second generation LungFit PH system as key reasons for the reset. Analyst Commentary Bullish Takeaways Bullish analysts still point to the second generation LungFit PH system as the main potential driver for higher long term revenue and margin expansion, which they see as central to justifying a higher valuation over time.
お知らせ • Apr 11Beyond Air, Inc. Receives Notice of Non-Compliance with Nasdaq Listing RuleOn April 7, 2026, Beyond Air, Inc. (the Company) received a written notification (the Notice) from the staff of the Listing Qualifications Department (the Staff) of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it no longer satisfies the $1.00 bid price requirement set in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the continued listing minimum bid price requirement exists if the deficiency continues for a period of thirty (30) consecutive business days (collectively, the Bid Price Rule). Based on the closing bid price of the Company's common stock, par value $0.0001 per share (the Common Stock), for the thirty (30) consecutive business days from February 23, 2026 to April 6, 2026, the Company no longer satisfies the Bid Price Rule. While companies are typically afforded a 180-calendar day compliance period to comply with the Bid Price Rule, the Notice stated that, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company was not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that the Company effected a reverse stock split over the prior one-year period. The Company effected a 1-for-20 reverse stock split on July 14, 2025. The Notice stated that the Company's securities will be subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the Panel) by April 14, 2026. Accordingly, the Company intends to timely request a hearing before the Panel, and at which point, such timely request will automatically stay any further suspension or delisting action by Nasdaq pending the Panel's decision. During the appeal process with the Panel, the Common Stock will continue to be listed and trade on Nasdaq. However, there can be no assurance that the Panel will grant the Company's request for continued listing or that the Company will be able to regain compliance and thereafter maintain its listing on Nasdaq. The Company intends to actively monitor the bid price of its Common Stock and is considering available options to regain compliance with the Nasdaq listing requirements, including such actions as effecting a reverse stock split to maintain its Nasdaq listing.
ナラティブの更新 • Apr 07XAIR: Later FDA Decision Will Still Unlock Key Future InflectionNarrative Update The analyst consensus price target for Beyond Air has shifted to $2, down from $6, as analysts point to reduced near term sales assumptions and a later FDA decision timeline for the second generation LungFit PH system, while still highlighting its potential importance for future revenue growth and profitability. Analyst Commentary Recent Street research reflects a more cautious stance on Beyond Air, with bearish analysts recalibrating expectations around both timing and scale of potential revenue from the second generation LungFit PH system.
お知らせ • Mar 28+ 1 more updateSteve Lisi Steps Down from the Board of Directors of Beyond Air, Inc, Effective March 27, 2026Beyond Air, Inc. announced that Steve Lisi has stepped down from the Board of Directors, effective March 27, 2026 to pursue other opportunities. For the past nine years, Mr. Lisi has led Beyond Air, guiding the development and launch of the Company’s LungFit PH. Under his leadership, the Company successfully brought this revolutionary technology to market and established a strong foundation for the LungFit franchise to accelerate Beyond Air’s growth.
ナラティブの更新 • Mar 24XAIR: Extended FDA Timeline Will Still Set Up Key Future InflectionAnalysts have cut their price target for Beyond Air to $2 from $6, citing revised sales timelines, with FDA approval for the second generation LungFit PH system now expected at the end of 2026, while still viewing that potential commercialization as central to future revenue growth and profitability. Analyst Commentary Recent price target revisions highlight a clear divide between long term optimism around LungFit PH and shorter term caution around execution and timing.
ナラティブの更新 • Mar 10XAIR: Future Regulatory Milestone And Capital Raise Will Underpin Potential UpsideAnalysts have cut their price target on Beyond Air to $2 from $6, citing updated sales estimates and a later expected FDA decision for the second generation LungFit PH system as key drivers of their revised outlook. Analyst Commentary Bearish analysts are signaling a more cautious stance on Beyond Air, with the latest research move cutting the price target to $2 from $6 and explicitly tying that change to revised expectations around the LungFit PH opportunity and timing.
New Risk • Feb 26New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.76m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings are forecast to decline by an average of 0.7% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (139% increase in shares outstanding). Market cap is less than US$10m (US$9.76m market cap). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (US$33m net loss in 2 years).
ナラティブの更新 • Feb 23XAIR: Later FDA Decision Will Still Support Long Term Upside PotentialAnalysts have cut their average price target for Beyond Air from about $12.33 to $8.67, reflecting updated expectations for slower revenue growth, a higher discount rate, and a higher future P/E multiple as they factor in revised sales estimates tied to the later FDA decision timing for the second generation LungFit PH system. Analyst Commentary Bullish Takeaways Bullish analysts still frame the second generation LungFit PH system as a central driver for Beyond Air's long term revenue profile, pointing to commercialization of this product as a potential turning point for the business once regulatory milestones are met.
Price Target Changed • Feb 20Price target increased by 16% to US$12.00Up from US$10.33, the current price target is an average from 2 analysts. New target price is 1,088% above last closing price of US$1.01. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$3.88 next year compared to a net loss per share of US$13.77 last year.
New Risk • Feb 20New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.7% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Earnings are forecast to decline by an average of 0.7% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (139% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$33m net loss in 2 years). Market cap is less than US$100m (US$11.4m market cap).
Reported Earnings • Feb 16Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2026 results: US$0.85 loss per share (improved from US$2.96 loss in 3Q 2025). Revenue: US$2.19m (up 105% from 3Q 2025). Net loss: US$7.34m (loss narrowed 44% from 3Q 2025). Revenue exceeded analyst estimates by 2.3%. Earnings per share (EPS) missed analyst estimates by 4.0%. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 7.7% growth forecast for the Medical Equipment industry in the US.
New Risk • Feb 13New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: US$37m Forecast net loss in 2 years: US$26m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (46% average weekly change). Shareholders have been substantially diluted in the past year (139% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$26m net loss in 2 years). Market cap is less than US$100m (US$10.7m market cap).
お知らせ • Feb 13+ 1 more updateBeyond Air, Inc. Maintains Earnings Guidance for the Fiscal Year Ending March 31, 2026Beyond Air, Inc. maintained earnings guidance for the fiscal year ending March 31, 2026. For the year, the company maintained its revenue guidance of $8 million to $10 million.
ナラティブの更新 • Feb 09XAIR: Bullish Coverage And New Capital Raise Will Support Future UpsideAnalysts now see Beyond Air's fair value holding at $6.00 per share, with a slightly higher discount rate and modestly adjusted revenue growth, profit margin, and future P/E assumptions following fresh bullish coverage that supports a constructive long term thesis on the stock. Analyst Commentary Recent coverage frames Beyond Air as a higher risk, higher reward idea, with the current fair value estimate of US$6.00 per share sitting against a backdrop of both optimism and clear caution.
お知らせ • Jan 27Beyond Air, Inc. to Report Q3, 2026 Results on Feb 13, 2026Beyond Air, Inc. announced that they will report Q3, 2026 results Pre-Market on Feb 13, 2026
ナラティブの更新 • Jan 25XAIR: Expanded Distribution And Fresh Capital Will Support Future UpsideAnalysts have kept their fair value target for Beyond Air steady at US$6.00, while adjusting their models to reflect updated assumptions on discount rate, revenue growth, profit margin and future P/E following recent bullish Street research coverage. Analyst Commentary While the latest Street coverage has been supportive, some bearish analysts continue to flag risks that they believe are not fully captured in the current US$6.00 fair value estimate.
お知らせ • Jan 14+ 1 more updateXTL Biopharmaceuticals Ltd. (TASE:XTLB) signed a letter of intent to acquire 85% stake in NeuroNos Limited from Beyond Air, Inc. (NasdaqCM:XAIR).XTL Biopharmaceuticals Ltd. (TASE:XTLB) signed a letter of intent to acquire 85% stake in NeuroNos Limited from Beyond Air, Inc. (NasdaqCM:XAIR) on January 13, 2026. A cash consideration of $1 million will be paid by XTL Biopharmaceuticals Ltd. The consideration consists of American Depositary Shares of XTL Biopharmaceuticals Ltd. to be issued as shall be required for Beyond Air, Inc. to beneficially own, as of the closing date of the Transaction, 19.99% of the issued and outstanding share capital of XTL Biopharmaceuticals Ltd. and three-year warrants of XTL Biopharmaceuticals Ltd. to be issued in such amount as necessary to ensure that Beyond Air, Inc. shall continue to maintain the Beneficial Ownership in relation to the exercise of certain existing XTL Biopharmaceuticals Ltd. warrants and any other issuances to employees and officers of NeuroNOS. Cash milestone payments in an aggregate amount of up to US$5,500,000, subject to the achievement of certain specified clinical and regulatory milestones, with an option for XTL Biopharmaceuticals Ltd., under certain circumstances, to discharge all such milestone payment obligations by making a single lump sum cash payment of US$4,000,000. Additionally, the LOI includes the payment of commercial milestone amounts by XTL Biopharmaceuticals Ltd. to Beyond Air, Inc based on cumulative net sales of the first NeuroNOS product, ranging from US$2,000,000 to US$12,500,000, upon attainment of specified net sales thresholds. Hence, XTL Biopharmaceuticals Ltd. will pay an earnout/contingent payment of $18 million cash. As part of consideration, $19 million is paid towards common equity of NeuroNos Limited. The transaction will be financed through equity investment of $2 million. The transaction is subject to approval by regulatory board / committee, approval of offer by acquirer shareholders, consummation of due diligence investigation, definitive agreement and third party approval needed. The LOI contemplates that XTL intends to extend to the other shareholders of NeuroNOS, who collectively hold approximately 15% of the issued and outstanding share capital of NeuroNOS not owned by XAIR, the opportunity, exercisable within a specified period following the consummation of the Transaction, to exchange their Remaining Shares for ordinary shares of XTL, on terms and conditions to be set forth in the definitive agreements.
New Risk • Jan 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 45% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (45% average weekly change). Shareholders have been substantially diluted in the past year (122% increase in shares outstanding). Market cap is less than US$10m (US$7.02m market cap).
ナラティブの更新 • Jan 11XAIR: Expanded Global Distribution And Recent Financing Will Support Future UpsideAnalysts have revised their price target for Beyond Air to US$6.00, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E multiples, which leaves the fair value estimate unchanged at US$6.00. What's in the News Beyond Air updated its earnings guidance for the fiscal year ending March 31, 2026, with revenue now guided to a range of US$8 million to US$10 million (Corporate guidance).
お知らせ • Jan 01+ 1 more updateBeyond Air, Inc. Announces Executive Changes, Effective as of January 5, 2026Beyond Air, Inc. announced on December 24, 2025, the Board of Directors of the company approved the appointment of Daniel Moorhead as the Company’s principal financial officer and principal accounting officer, effective as of January 5, 2026 (the “Effective Date”). Mr. Moorhead will replace Denton “Duke” Dewrell as the Company’s principal financial officer and principal accounting officer as of the Effective Date. Mr. Dewrell had temporarily assumed the role and responsibility of the principal financial officer and principal accounting officer of the Company, and will remain employed by the Company as its controller. Mr. Moorhead, age 53, most recently served as the Chief Financial Officer of Zynex, Inc. from June 2017 to August 2025. Prior to his role with Zynex, Mr. Moorhead previously served as Chief Financial Officer of Evolving Systems, Inc. from January 2016 until May 2017, after having served as Vice President of Finance & Administration from December 2011 through December 2015 and in other financial management roles from 2002-2005 and 2008-2011. Mr. Moorhead is a CPA and holds a B.B.A. in Accounting from the University of Northern Colorado.
ナラティブの更新 • Dec 26XAIR: Expanded Global Distribution And New Financing Will Support Upside PotentialAnalysts have modestly raised their price target on Beyond Air to reflect a slightly higher long term growth outlook and valuation multiple, while incorporating a more conservative discount rate and largely unchanged profit margin assumptions. What's in the News Signed multiple new international distribution agreements for LungFit PH across Germany, Brazil, Austria, the Netherlands and Sri Lanka, bringing total coverage to 39 countries and over three billion people (Key Developments).
お知らせ • Dec 22Beyond Air, Inc., Annual General Meeting, Jan 30, 2026Beyond Air, Inc., Annual General Meeting, Jan 30, 2026. Location: 900 stewart avenue, suite 301, garden city, new york 11530, new york United States
ナラティブの更新 • Dec 12XAIR: Stronger Revenue Outlook And Financing Will Support Future Upside PotentialAnalysts have raised their price target on Beyond Air to 6.00 dollars from 5.00 dollars, citing slightly stronger expected revenue growth, modestly improved profit margins, and a higher anticipated future price to earnings multiple despite a higher discount rate. What's in the News Chief Financial Officer Doug Larson has resigned to pursue another opportunity and will remain in his role until December 5, 2025.
お知らせ • Nov 27Beyond Air, Inc. Announces CFO Changes, Effective December 5, 2025Beyond Air, Inc. announced that Doug Larson has resigned as Chief Financial Officer to pursue another opportunity. Mr. Larson will continue to serve as CFO through December 5, 2025, at which time the CFO responsibilities at the Company will be assumed on an interim basis by Duke Drewell, the Company’s Controller. Beyond Air has launched a search for a permanent successor. Mr. Larson will serve in an advisory role at the Company through calendar year end 2025 to support a smooth transition. Mr. Larson’s departure is not the result of any disagreements with the Company on any matter relating to its financial statements, internal control over financial reporting, operations, policies or practices.
New Risk • Nov 21New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.85m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (122% increase in shares outstanding). Market cap is less than US$10m (US$9.85m market cap).
Major Estimate Revision • Nov 17Consensus revenue estimates fall by 36%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from US$13.4m to US$8.58m. Forecast losses increased from -US$3.47 to -US$3.74 per share. Medical Equipment industry in the US expected to see average net income growth of 18% next year. Consensus price target down from US$12.33 to US$10.33. Share price fell 21% to US$1.38 over the past week.
Reported Earnings • Nov 12Second quarter 2026 earnings: EPS and revenues miss analyst expectationsSecond quarter 2026 results: US$1.25 loss per share (improved from US$5.67 loss in 2Q 2025). Revenue: US$1.82m (up 128% from 2Q 2025). Net loss: US$7.94m (loss narrowed 41% from 2Q 2025). Revenue missed analyst estimates by 28%. Earnings per share (EPS) also missed analyst estimates by 58%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US.
お知らせ • Nov 11+ 1 more updateBeyond Air, Inc. Announces Executive ChangesBeyond Air, Inc. announced that Board member Bob Goodman as Interim Chief Commercial Officer to lead commercial strategy and team transitioning from David Webster. Bob brings decades of commercial leadership across medtech and pharma, including senior roles at BioTelemetry and Philips Healthcare, and will oversee U.S. and international commercial strategy, team expansion, and channel optimization. Appointed Robert (Bob) Goodman interim Chief Commercial Officer following the departure of David Webster. Robert, who joined the Board of Beyond Air in June 2025, has held key leadership roles at a range of high-performing organizations, including BioTelemetry, Philips Healthcare, Cardiocore, Thermo Fisher Scientific, and Pfizer. His career spans public companies, private equity–backed businesses, and early-stage ventures, where he has consistently driven innovation, operational scale, and commercial success.
お知らせ • Nov 06Beyond Air, Inc. announced that it expects to receive $32.05 million in funding from Streeterville Capital, LLCBeyond Air, Inc. announced that it has entered into an equity purchase agreement to issue common shares for gross proceeds of $20,000,000 and also entered into a note purchase agreement to issue secured non-convertible promissory note in the principal amount of $12,050,000 for gross proceeds of $12,050,000 for aggregate proceeds of $32,050,000 on November 4, 2025. The transaction includes participation from new investor, Streeterville Capital, LLC. The note will accrue interest at the rate of 15% per annum, with no interest accruing for the first 12 months following issuance and will mature in 24 months following the date of issuance. The equity purchase agreement will terminate on the earlier of the date on which the investor shall have purchased put shares pursuant the agreement equal to the maximum commitment amount, within 24 months after the date of the agreement, written notice of termination by the company to the investor or the date that, pursuant to or within the meaning of any bankruptcy law, the company commences a voluntary case or any person commences a proceeding against the company, a custodian is appointed for the company or for all or substantially all of its property or the company makes general assignment for the benefit of its creditors. The company agreed to pay $50,000 to Streeterville to cover its transaction costs, resulting in the company receiving net proceeds of $32,000,000. On the same date the company issued secured promissory note in the principal amount of $12,050,000 for gross proceeds of $12,050,000 in its first tranche.
ナラティブの更新 • Nov 01XAIR: Global Network Expansion Will Drive Long-Term Market PresenceAnalysts have modestly maintained their price target for Beyond Air at $12.33 per share. They cite steady expectations around revenue growth and profit margins, even though there have been minor adjustments to other financial assumptions.
お知らせ • Oct 23Beyond Air, Inc. to Report Q2, 2026 Results on Nov 10, 2025Beyond Air, Inc. announced that they will report Q2, 2026 results on Nov 10, 2025
ナラティブの更新 • Oct 18Global Expansion And Next-Generation Respiratory Care Will Transform MarketsAnalysts have raised their price target for Beyond Air from $11.20 to $12.33, reflecting improved revenue growth expectations and a notable increase in projected profit margins. What's in the News The global distribution network for LungFit PH has been expanded, with new agreements in Japan, South Korea, Costa Rica, Guatemala, and El Salvador.
New Risk • Sep 23New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: US$42m Forecast net loss in 3 years: US$3.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$36m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (125% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$3.0m net loss in 3 years). Revenue is less than US$5m (US$4.8m revenue). Market cap is less than US$100m (US$12.3m market cap).
ナラティブの更新 • Sep 04Global Expansion And Next-Generation Respiratory Care Will Transform MarketsWith minimal changes in both the discount rate and future P/E, Beyond Air’s consensus analyst price target remained effectively unchanged at $11.20. What's in the News Expanded global LungFit PH distribution network to 34 countries, including new agreements in Japan (with AMCO), South Korea, Costa Rica, Guatemala, and El Salvador.
Major Estimate Revision • Aug 19Consensus revenue estimates decrease by 16%, EPS upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$16.0m to US$13.4m. EPS estimate increased from -US$4.08 to -US$4.03 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$19.40 to US$11.20. Share price fell 28% to US$2.29 over the past week.
Reported Earnings • Aug 14First quarter 2026 earnings: EPS misses analyst expectationsFirst quarter 2026 results: US$1.53 loss per share (improved from US$5.32 loss in 1Q 2025). Revenue: US$1.76m (up 158% from 1Q 2025). Net loss: US$7.69m (loss narrowed 37% from 1Q 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 16%. Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.
お知らせ • Aug 13Beyond Air, Inc. Reaffirms Earnings Guidance for the Fiscal Year Ending March 31, 2026Beyond Air, Inc. reaffirmed earnings guidance for the fiscal year ending March 31, 2026. For the period, the company, reaffirmed its revenue guidance of $12 million to $16 million.
お知らせ • Jul 25Beyond Air, Inc. to Report Q1, 2026 Results on Aug 12, 2025Beyond Air, Inc. announced that they will report Q1, 2026 results on Aug 12, 2025
Major Estimate Revision • Jul 23Consensus EPS estimates upgraded to US$4.31 lossThe consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$5.00 to -US$4.31 per share. Revenue forecast unchanged from US$15.9m at last update. Medical Equipment industry in the US expected to see average net income growth of 13% next year. Consensus price target down from US$45.00 to US$36.60. Share price rose 3.7% to US$3.36 over the past week.
お知らせ • Jun 19+ 1 more updateBeyond Air, Inc. Provides Earnings Guidance for the Quarter Ending June 30, 2025 and for the Year Ending March 31, 2025Beyond Air, Inc. provided earnings guidance for the quarter ending June 30, 2025 and for the year ending March 31, 2025. For the quarter, the company expects to report revenue of at least $1.7 million. For the year, the company is providing revenue guidance of $12 to $16 million.
Reported Earnings • Jun 18Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: US$0.63 loss per share (improved from US$1.82 loss in FY 2024). Revenue: US$3.71m (up 220% from FY 2024). Net loss: US$46.6m (loss narrowed 23% from FY 2024). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) exceeded analyst estimates by 7.0%. Revenue is forecast to grow 38% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.
New Risk • Jun 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (88% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$9.8m net loss in 3 years). Revenue is less than US$5m (US$3.0m revenue). Market cap is less than US$100m (US$15.5m market cap).
お知らせ • May 20Beyond Air, Inc. to Report Q4, 2025 Results on Jun 17, 2025Beyond Air, Inc. announced that they will report Q4, 2025 results on Jun 17, 2025
新しいナラティブ • Apr 14The Next-Generation LungFit PH System Will Open New Markets International revenue could significantly impact growth due to CE Mark approval and distribution partnerships, especially in the EU.
Recent Insider Transactions • Mar 18Independent Director recently bought US$250k worth of stockOn the 14th of March, Robert Carey bought around 1m shares on-market at roughly US$0.25 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$365k more in shares than they have sold in the last 12 months.
Reported Earnings • Feb 11Third quarter 2025 earnings: EPS and revenues exceed analyst expectationsThird quarter 2025 results: US$0.15 loss per share (improved from US$0.50 loss in 3Q 2024). Revenue: US$1.07m (up 174% from 3Q 2024). Net loss: US$13.0m (loss narrowed 20% from 3Q 2024). Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 6.3%. Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US.
お知らせ • Feb 07Beyond Air Receives 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid RequirementBeyond Air, Inc. announced it received a notification from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has been granted an additional 180-day compliance period, or until August 4, 2025 to regain compliance with Nasdaq’s minimum bid price rule (Rule 5550(a)(2)). The notification has no immediate effect on the listing of the Company’s common stock, and the common stock will continue to trade on the Nasdaq Capital Market under the symbol "XAIR." Nasdaq’s determination is based on the Company meeting all other applicable requirements for listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period and, if necessary, by effecting a reverse share split. In a notification letter dated August 8, 2024, Nasdaq had first informed the Company that, based on the previous 30 consecutive business days, the Company’s common stock no longer met the minimum $1.00 bid price per share requirement and in accordance with Nasdaq’s Listing Rules, the Company was provided 180 calendar days, or until February 4, 2025, to regain compliance. The Company did not regain compliance with the minimum $1.00 bid price per share requirement during the first 180 calendar day compliance period and submitted a written request to Nasdaq’s staff to afford the Company an additional 180-day compliance period to cure the deficiency, which the Company was granted in a notification letter dated February 5, 2025. If at any time before August 4, 2025, the closing bid price of the Company’s security is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule and this matter will be closed. However, Nasdaq may, in its discretion, require the Company to maintain a bid price of at least $1.00 per share for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.
お知らせ • Jan 28Beyond Air, Inc. to Report Q3, 2025 Results on Feb 10, 2025Beyond Air, Inc. announced that they will report Q3, 2025 results After-Market on Feb 10, 2025
お知らせ • Jan 25Beyond Air®? Announces LungFit®? PH Receives Market Authorization in AustraliaBeyond Air, Inc. announced that the LungFit®? PH has received market authorization from the Australian Therapeutic Goods Administration (TGA) for sale as a Class IIb medical device to deliver nitric oxide, a vasodilator, generated by the device into the inspiratory limb of the patient breathing circuit of a ventilator in a way that provides a constant concentration of nitric oxide, as set by the user, to the patient throughout the inspired breath. LungFit PH, the first device in the LungFit therapeutic platform of nitric oxide generators, leverages the company's patented Ionizer®? technology and has already received FDA clearance in the United States and European CE Mark approval. LungFit PH uses Ionizer technology to generate unlimited on-demand NO from ambient air and deliver it to a ventilator circuit, regardless of dose or flow. The device uses a compressor to drive room air through a plasma chamber where pulses of electrical discharge are created between two electrodes. The LungFit PH system ionizes the nitrogen and oxygen molecules, forming NO with low levels of nitrogen dioxide (NO2) created as a byproduct. The gas is then passed through a Smart Filter, which removes toxic NO2 from the internal circuit. LungFit PH represents a significant step forward in sustainable healthcare solutions. Since the device generates NO conveniently and cleanly from ambient air, without the need for tanks or chemicals, it is highly energy-efficient, using only the power equivalent to a 60-watt light bulb. By eliminating the emissions associated with truck transport and cylinder refills, LungFit PH supports hospital sustainability initiatives, helping facilities reduce their carbon footprint while delivering critical care to patients. For the approved indications, the novel LungFit PH system is designed to deliver a dosage of NO to the lungs that is consistent with the current standard of care for delivery of 20 ppm NO, with a range of 0.5 ppm – 80 ppm (low concentration NO) for ventilated patients. Each Smart Filter will last 12 hours regardless of ventilator demands, and replacing a filter only takes seconds.
お知らせ • Dec 04Beyond Air, Inc. Receives CE Mark in Europe for the LungFit PH SystemBeyond Air, Inc. announced European CE mark approval of the LungFit PH system. This CE mark approval allows Beyond Air to market LungFit PH in the European Union and all other countries that recognize this certification. LungFit PH, the first device in the LungFit therapeutic platform of nitric oxide generators, leverages the company's patented Ionizer technology and has already received FDA approval in the United States. Under the terms of Beyond Air’s existing commercialization agreement with Getz Healthcare for LungFit PH, Getz will make a $1 million milestone payment to Beyond Air upon CE mark certification. In addition, Beyond Air will receive ongoing royalty payments based on LungFit PH net sales. The partnership provides access to hospitals in Australia, New Zealand, Thailand, Philippines, Taiwan, Hong Kong, Malaysia, Pakistan, Singapore and Vietnam. The specific indications for LungFit PH under CE Mark certification include: 1) the treatment of infants > 34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation. 2) the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function. LungFit PH uses Ionizer technology to generate unlimited on-demand NO from ambient air and deliver it to a ventilator circuit, regardless of dose or flow. The device uses a compressor to drive room air through a plasma chamber where pulses of electrical discharge are created between two electrodes. The LungFit PH system ionizes the nitrogen and oxygen molecules, forming NO with low levels of nitrogen dioxide (NO2) created as a byproduct. The gas is then passed through a Smart Filter, which removes toxic NO2 from the internal circuit. LungFit PH represents a significant step forward in sustainable healthcare solutions. Since the device generates NO conveniently and cleanly from ambient air, without the need for tanks or chemicals, it is highly energy-efficient, using only the power equivalent to a 60-watt light bulb. By eliminating the emissions associated with truck transport and cylinder refills, LungFit PH supports hospital sustainability initiatives, helping facilities reduce their carbon footprint while delivering critical care to patients. For the approved indications, the novel LungFit PH system is designed to deliver a dosage of NO to the lungs that is consistent with the current standard of care for delivery of 20 ppm NO, with a range of 0.5 ppm – 80 ppm (low concentration NO) for ventilated patients. Each Smart Filter will last 12 hours regardless of ventilator demands, and replacing a filter only takes seconds. Potential customers can visit the LungFit PH website, www.lungfitph.com, for additional information, including the product label, and to sign up for updates.
お知らせ • Nov 19Beyond Air, Inc. announced that it has received $3.35 million in funding from Avenue Capital Group, LLCOn November 18, 2024 Beyond Air, Inc. closed the transaction.
Reported Earnings • Nov 14Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2025 results: US$0.28 loss per share (improved from US$0.51 loss in 2Q 2024). Net loss: US$13.4m (loss narrowed 18% from 2Q 2024). Revenue missed analyst estimates by 23%. Earnings per share (EPS) exceeded analyst estimates by 1.4%. Revenue is forecast to grow 92% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US.
Major Estimate Revision • Nov 13Consensus revenue estimates decrease by 56%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$8.69m to US$3.79m. EPS estimate increased from -US$0.944 to -US$0.88 per share. Medical Equipment industry in the US expected to see average net income growth of 20% next year. Consensus price target down from US$3.75 to US$2.50. Share price was steady at US$0.48 over the past week.
New Risk • Nov 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 128% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Shareholders have been substantially diluted in the past year (128% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$4.5m net loss in 3 years). Revenue is less than US$5m (US$1.8m revenue). Market cap is less than US$100m (US$34.7m market cap).
お知らせ • Oct 30Beyond Air, Inc. to Report Q2, 2025 Results on Nov 11, 2024Beyond Air, Inc. announced that they will report Q2, 2025 results After-Market on Nov 11, 2024
お知らせ • Oct 10Beyond Air, Inc., Annual General Meeting, Dec 09, 2024Beyond Air, Inc., Annual General Meeting, Dec 09, 2024.
お知らせ • Sep 27+ 1 more updateBeyond Air, Inc. Withdraws Its Previous Revenue Guidance for Fiscal Year 2025Beyond Air, Inc. is withdrawing its previous revenue guidance for fiscal year 2025.
Recent Insider Transactions Derivative • Aug 25Chief Executive Officer of NeuroNOS notifies of intention to sell stockAmir Avniel intends to sell 180k shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of August. If the sale is conducted around the recent share price of US$0.46, it would amount to US$83k. Since December 2023, Amir's direct individual holding has increased from 431.76k shares to 438.03k. Company insiders have collectively bought US$2.9m more than they sold, via options and on-market transactions, in the last 12 months.
Major Estimate Revision • Aug 13Consensus EPS estimates upgraded to US$1.01 loss, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$9.67m to US$9.00m. 2025 losses expected to reduce from -US$1.16 to -US$1.01 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$5.17 to US$4.33. Share price fell 12% to US$0.43 over the past week.
お知らせ • Aug 07Beyond Air, Inc. Provides Earnings Guidance for the Year 2025Beyond Air, Inc. provided earnings guidance for the year 2025, Revenue is expected to be greater than $10 million for Fiscal Year 2025.
お知らせ • Jul 24Beyond Air, Inc. to Report Q1, 2025 Results on Aug 06, 2024Beyond Air, Inc. announced that they will report Q1, 2025 results After-Market on Aug 06, 2024
お知らせ • Jul 09Beyond Air, Inc. announced that it has received $0.128 million in fundingOn July 9, 2024, Beyond Air, Inc. closed the transaction. The transaction included participation from two investors.
お知らせ • Jul 03+ 3 more updatesBeyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell Small Cap Comp Value IndexBeyond Air, Inc.(NasdaqCM:XAIR) dropped from Russell Small Cap Comp Value Index
Major Estimate Revision • Jul 01Consensus revenue estimates decrease by 27%, EPS upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from US$13.2m to US$9.67m. EPS estimate increased from -US$1.75 to -US$1.15 per share. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target down from US$12.60 to US$5.88. Share price fell 60% to US$0.54 over the past week.
Price Target Changed • Jun 25Price target decreased by 55% to US$5.88Down from US$13.00, the current price target is an average from 4 analysts. New target price is 805% above last closing price of US$0.65. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$1.15 next year compared to a net loss per share of US$1.82 last year.
お知らせ • Jun 25Beyond Air, Inc. Updates Revenue Guidance for the Fiscal Year 2025Beyond Air, Inc. updated revenue guidance for the fiscal year 2025. For the year, the company updated revenue guidance to greater than $10 million, from the previous guidance of $12 million to $16 million.
お知らせ • Jun 15Beyond Air Appoints David Webster as Chief Commercial Officer, Effective from July 8, 2024Beyond Air, Inc. announced the appointment of David Webster as Chief Commercial Officer of the Company, effective July 8, 2024. Mr. Webster has successfully developed and executed several commercial strategies for medical devices and therapeutics, primarily in the hospital space. Mr. Webster brings decades of experience in the life sciences industry, including leading several programs through clinical development, regulatory submissions, and global commercialization. Most recently, he served as Chief Executive Officer at Body Vision Medical, a medical device company dedicated to making artificial intelligence (AI)-driven real-time imaging navigation the standard of care for the diagnosis and treatment of endoluminal cancer. As CEO, he led the global commercialization of the Lung Vision system, expanding it into new medical applications. Prior to Body Vision, he spent nearly 18 years at NeuroLogica. During his tenure, he served as NeuroLogica’s Vice President of Global Sales and Marketing leading up to and after the company’s acquisition by Samsung Electronics Co. Ltd. in 2013. Following the acquisition, Mr. Webster served as Chief Marketing Officer and Chief Operating Officer for Samsung NeuroLogica. Mr. Webster holds a Master of Science degree in Business Administration and Management from Troy University and a Bachelor of Arts degree in Psychology from The Citadel.
お知らせ • May 25Beyond Air, Inc. to Report Q4, 2024 Results on Jun 24, 2024Beyond Air, Inc. announced that they will report Q4, 2024 results on Jun 24, 2024
お知らせ • Mar 23Beyond Air, Inc. has completed a Follow-on Equity Offering in the amount of $16.000003 million.Beyond Air, Inc. has completed a Follow-on Equity Offering in the amount of $16.000003 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 9,638,556 Price\Range: $1.66 Discount Per Security: $0.116 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 9,638,556 Transaction Features: Registered Direct Offering
New Risk • Mar 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 6.2% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (US$689k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$78m net loss in 3 years). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$74.8m market cap).
お知らせ • Mar 22Beyond Air, Inc. has filed a Follow-on Equity Offering in the amount of $16.000003 million.Beyond Air, Inc. has filed a Follow-on Equity Offering in the amount of $16.000003 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 9,638,556 Price\Range: $1.66 Discount Per Security: $0.116 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 9,638,556 Transaction Features: Registered Direct Offering
Major Estimate Revision • Feb 19Consensus revenue estimates decrease by 15%, EPS upgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$1.69m to US$1.43m. EPS estimate increased from -US$2.05 to -US$1.95 per share. Medical Equipment industry in the US expected to see average net income growth of 15% next year. Consensus price target of US$13.00 unchanged from last update. Share price fell 9.8% to US$1.94 over the past week.
お知らせ • Jan 27Beyond Air, Inc., Annual General Meeting, Mar 08, 2024Beyond Air, Inc., Annual General Meeting, Mar 08, 2024, at 16:30 US Eastern Standard Time. Location: Beyond Air, Inc., 900 Stewart Avenue, Suite 301 Garden City New York United States Agenda: To elect seven directors, each to hold office until the 2025 Annual Meeting of Stockholders and until his or her successor is elected and qualified; to ratify the appointment of Marcum LLP as independent registered public accounting firm for fiscal year ending March 31, 2024; to approve the Sixth Amended and Restated 2013 Equity Incentive Plan to increase the number of shares reserved for issuance by 3,000,000; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
お知らせ • Jan 19Beyond Air, Inc. to Report Q3, 2024 Results on Feb 12, 2024Beyond Air, Inc. announced that they will report Q3, 2024 results on Feb 12, 2024
Recent Insider Transactions • Dec 22Independent Director recently bought US$2.0m worth of stockOn the 18th of December, Robert Carey bought around 1m shares on-market at roughly US$1.64 per share. This transaction increased Robert's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$3.6m more in shares than they have sold in the last 12 months.
Major Estimate Revision • Nov 20Consensus revenue estimates fall by 40%The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$2.86m to US$1.72m. Forecast losses increased from -US$1.90 to -US$2.02 per share. Medical Equipment industry in the US expected to see average net income growth of 22% next year. Consensus price target down from US$14.17 to US$12.50. Share price fell 26% to US$1.50 over the past week.
New Risk • Nov 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$54m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Revenue is less than US$1m (US$298k revenue). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$43m net loss in 3 years). Shareholders have been diluted in the past year (6.9% increase in shares outstanding). Market cap is less than US$100m (US$44.8m market cap).
Price Target Changed • Nov 15Price target decreased by 12% to US$13.00Down from US$14.83, the current price target is an average from 6 analysts. New target price is 829% above last closing price of US$1.40. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$1.89 next year compared to a net loss per share of US$1.86 last year.
お知らせ • Oct 20Beyond Air, Inc. to Report Q2, 2024 Results on Nov 13, 2023Beyond Air, Inc. announced that they will report Q2, 2024 results on Nov 13, 2023
